p16-093
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03073395)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- p16-093
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03444844 | Phase 1 | Mar 31, 2018 | Five Eleven Pharma, Inc., Indiana University |
| NCT03073395 | Early Phase 1 (Phase 1) | Jun 1, 2017 | Five Eleven Pharma, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Five Eleven Pharma, Inc. | For profit | 2 | 2 | 1 | 2017 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1